From a 95% remission rate in Japan to $81.6 billion in U.S. savings since 2015 — a data-driven look at where biosimilars stand today, and where the gaps remain.
Lauren Gordon
Advertisement
Lauren Gordon is the Lead Strategic Content Lead at Managed Healthcare Executive, where she covers the policy, business, and clinical trends shaping the healthcare industry — from biosimilar market dynamics to payer strategy and specialty drug spending. Her reporting translates dense regulatory and financial data into clear, actionable insight for healthcare executives, payers, and providers.
Experience
Before joining MHE, Lauren wrote health profiles for Parade.com and helped launch the healthy eating vertical at The Daily Meal, building a foundation in consumer health journalism before shifting into healthcare policy and industry reporting. Throughout her career, she has worked directly with both patients and providers to develop accurate, accessible content on complex healthcare and policy topics.
Education
A Temple University graduate, Lauren earned her B.A. in Journalism & Communications.
Articles by Lauren Gordon
As concerns about GLP-1 costs grow, employers could be overlooking an even more pervasive condition driving healthcare spending.
From $37 billion to nearly $71 billion in a decade: a look at the forces driving biosimilars' next growth phase.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Heart data in sleep study predicts atrial fibrillation, heart failure years in advance
2
Staci E. Beamer, M.D., on the rise of robotic lung surgery | CHEST 2026
3
Will Carroll, Pharm.D., on developing future pharmacy executives | HSES 2026
4
Janjri Desai, Pharm.D., on pharmacy value, billing parity and workforce | HSES 2026
5